1616 results about "Rectal carcinoma" patented technology

There is provided herein a compound of formula (I) wherein R1, R2, R3, R4, A, X1, Y, L, Z, R5, R6a, R6b, W and R7 are as defined herein, for use in the treatment of colorectal and / or lung cancer.

The invention relates to the field of biotechnology and medicine, and more particularly to a polypeptide having the amino acid sequence SEQ ID NO: 1 and being capable of inhibiting RAS-GTPase activity, to the use of said polypeptide to produce a drug for treating stomach cancer or rectal cancer in a dose of 0.81-3.00 mg / kg, as well as to a drug based on said polypeptide for the treatment of stomach cancer or rectal cancer, and to a method for treating stomach cancer or rectal cancer by intraperitoneally administering said drug to a subject in an amount of 150 ml twice at an interval of 7 days.

The present invention is directed to the compounds of Formula (IV) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

The present disclosure is directed to compounds of Formula I: wherein Z1, Z2, R1, R2, R3, and R4 are described herein, which are spirocyclic compounds for inhibiting Werner Syndrome dsDNA helicase (WRN) and methods of treating disease using these compounds. This disclosure further provides compounds and their use for the treatment of cancers characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), including colorectal, gastric, endometrial and ovarian cancer.

The invention relates to the technical field of assessment and early warning systems, and particularly discloses a rectal cancer operation risk assessment and early warning system based on multi-modal data fusion, which comprises a multi-modal data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic risk assessment module, an intelligent early warning module and a system self-checking module. By integrating multi-modal data and dynamically allocating weights, real-time risk updating in the whole operation period is achieved, the comprehensiveness, timeliness and precision of risk assessment are comprehensively improved by combining the grading early warning function, the autonomous detection calibration function and the risk tracing and countermeasure matching function, long-term reliable operation of the system is guaranteed, powerful support is provided for clinical decision making, and the risk assessment method is suitable for clinical decision making. The surgical risk and the complication occurrence rate are effectively reduced.

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

The invention discloses sesquiterpenoids as well as a preparation method and application thereof. The structure of the sesquiterpenoids is shown in the specification. The sesquiterpenoids of # imgabs0 can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, kidney cancer and skin cancer. According to the invention, various natural product extracts are subjected to activity screening, the sesquiterpenoids derived from the rattan chrysanthemum have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low.

The invention belongs to the technical field of polypeptides, and discloses a polypeptide targeting HER2 protein, a radioactive polypeptide and a preparation method and application of the radioactive polypeptide, and the structural formula of the radioactive polypeptide is as follows: # imgabs0 #. Through in-vitro radiochemical property research and in-vivo stability research, the 68Ga-DOTA-AON is found to be high in stability and hydrophilic; through cell uptake research and receptor binding force research, the 68Ga-DOTA-AON is found to have relatively high affinity to HER2 protein expressed by HT-29 cells; the tumor imaging effect of the radioactive polypeptide 68Ga-DOTA-AON is investigated through small animal PET / CT, and it is found that [68Ga] Ga-DOTA-AON can be used for in-vivo imaging of HER2 positive colorectal cancer.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a pair of diastereoisomers in fresh bamboo juice as well as a preparation method and application of the diastereoisomers, in the diastereoisomers, a formula I is a dextroisomer and is named as (+)-fresh bamboo juice phenol A, and a formula II is a levoisomer and is named as (-)-fresh bamboo juice phenol A. According to the invention, a pair of diastereoisomer compounds (+)-fresh bamboo juice phenol A and (-)-fresh bamboo juice phenol A are successfully obtained from fresh bamboo juice, and an in-vitro cell test shows that the (+)-fresh bamboo juice phenol A has a remarkable inhibition effect on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung cancer, pancreatic cancer, colorectal cancer, and solid tumors. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described.

The invention belongs to the technical field of medicine, and discloses a method and system for predicting anastomotic fistula occurring after colorectal cancer operation, and the method comprises the steps: obtaining clinical pathology data and laboratory analysis data of a patient; filling missing data in the clinical pathology data and the laboratory analysis data; screening key indexes by using a single-factor regression analysis technology; performing multi-factor regression analysis on the key indexes, and screening to obtain independent prediction factors for predicting whether the colorectal cancer patient has the anastomotic fistula or not after operation; based on the independent prediction factors obtained through screening, an anastomotic fistula prediction model is constructed and trained, and the trained anastomotic fistula prediction model is used for predicting the postoperative anastomotic fistula occurrence probability of the colorectal cancer patient. The method can more accurately predict the probability of occurrence of anastomotic fistula of a colorectal cancer patient after an operation, has better accuracy and reliability, can facilitate preoperative prediction of the probability of occurrence of anastomotic fistula for clinical doctors, and assists in guiding treatment decision.

The invention relates to the technical field of biomedicine, and discloses a rectal cancer postoperative recurrence risk prediction method based on a prediction model, and the method comprises the steps: obtaining a patient tumor in the in-vivo image data of a rectal cancer patient; extracting imaging features of the tumor of the patient, and identifying recurrence risk features of the rectal cancer patient from the imaging features; analyzing clinical pathological characteristics of the rectal cancer patient according to the preoperative evaluation data and the postoperative pathological report; key recurrence influence factors of the rectal cancer patients are identified, recurrence events and follow-up visit time of the rectal cancer patients are identified, risk scoring is carried out on the rectal cancer patients, and a risk scoring result is obtained; based on the risk scoring result, the recurrence risk stratification of the rectal cancer patient is defined, postoperative recurrence risk analysis is conducted on the rectal cancer patient in combination with the recurrence risk stratification, the recurrence risk characteristics and the risk scoring result, and a risk analysis result is obtained. According to the invention, the comprehensiveness and accuracy of the rectal cancer recurrence risk analysis result can be improved.

The invention discloses an interpretability analysis and decision sharing verification method and system for a rectal cancer prognosis model, and relates to the field of medical artificial intelligence interpretability. The method comprises the following steps: carrying out gradient weighting class activation mapping analysis on a prognosis model to generate an image thermodynamic diagram; calculating the contribution degree of the multi-modal features by using an SHAP interpreter; an integrated visual interface is constructed, and patient data, model prediction and the explanation result are presented to a doctor together; the doctor performs independent risk assessment based on the interface information; finally, decisions of doctors and the model are compared, and model auxiliary efficiency is evaluated. Through a doctor-model decision sharing verification mechanism which is explained and innovated in a multi-level mode, the transparency and clinical credibility of the complex AI prognosis model are remarkably improved, the value of time sequence data in dynamic risk assessment can be verified, and clinical landing application of the AI model is powerfully promoted.

The invention relates to the technical field of rectal cancer prognosis prediction, in particular to a rectal cancer prognosis prediction method and device based on a multi-modal image and electronic equipment. The method comprises the following steps: firstly, acquiring an MRI image and a pathological image of a patient as original input data; respectively preprocessing the MRI image and the pathological image by adopting a double-flow heterogeneous feature extractor; then, by establishing a dynamic association mechanism, the change of the mapping relation between the two kinds of modal feature data is tracked in real time, the dynamic association mechanism can adjust the feature weight in a self-adaptive mode, and key changes in the disease progress process are effectively captured; and finally, based on the obtained dynamic association feature data, applying a pre-trained prediction model to obtain a prognosis prediction result. The MRI image and the pathological image are effectively integrated, and the accuracy of predicting the disease progress and the prediction repeatability are improved.

The invention relates to paclitaxel ganoderma lucidum spore oil self-nanoemulsion composite particles with ganoderma lucidum spores as a carrier and a preparation method of the paclitaxel ganoderma lucidum spore oil self-nanoemulsion composite particles, and belongs to the technical field of medicines. Pretreated Ganoderma lucidum spores (GLS) are obtained through process screening and serve as a drug carrier, and paclitaxel-loaded Ganoderma lucidum spore oil self-nanoemulsion (PGS) is loaded into the Ganoderma lucidum spores (GLS) to obtain paclitaxel-loaded composite particles (PGS (at) GLS). An in-vitro release curve shows that the PGS-atGLS has the characteristic of slow release after reaching the intestinal tract; in-vivo pharmacodynamic experiments show that PGS-atGLS can significantly inhibit development and metastasis of mouse colorectal cancer; tumor tissue slice immunofluorescence analysis shows that PGS-atGLS can effectively play a role in treating colon cancer. The paclitaxel self-nanoemulsion-loaded ganoderma lucidum spore composite particles synergistically promote cancer immune circulation by inducing immunogen cell death and immunoregulation, significantly improve the treatment effect of colon cancer, and have good biological safety.

The invention relates to a methylation biomarker for detecting colorectal cancer or colorectal adenoma. The methylation biomarker comprises any one gene of SDC2, COL4A2 and C9H9orf50 or any combination of the SDC2, the COL4A2 and the C9H9orf50. Wherein a methylation target detection region of the SDC2 gene is a full-length region of chr8: 96494012-96494130 or a partial region of the full-length region of chr8: 96494012-96494130; a methylation target detection region of the COL4A2 gene is a full-length region of chr13: 110306814-110306983 or a part of the full-length region of the chr13: 110306814-110306983; and the methylation target detection region of the C9H9orf50 gene is the full-length region of chr9: 129620291-129620374 or a part of the full-length region of chr9: 129620291-129620374. According to the kit, methylation signals related to intestinal cancer and adenoma in excrement samples can be more accurately detected through detection in different combination modes of the three markers, the early effective diagnosis rate of colorectal cancer patients can be increased, and therefore the survival rate of the patients is increased, and prognosis is improved.

The invention discloses a marker combination, method and system for diagnosing colorectal cancer and application, and belongs to the technical field of cancer marker application. The marker combination disclosed by the invention can be used for judging whether a subject suffers from colorectal cancer or has the risk of suffering from colorectal cancer, and the performance is higher.

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.

The invention discloses application of MUC12 gene in preparation of drugs for reducing rectal cancer liver metastasis, and belongs to the technical field of medical biology. According to the invention, the clear relation between colorectal cancer liver metastasis and fructose metabolism reprogramming is revealed from a molecular mechanism for the first time. The invention provides a brand-new therapeutic target and strategy by determining the brand-new transfer promoting factor MUC12 and the mediated fructose metabolism regulation effect thereof. Different from the traditional therapy only aiming at the strategies of tumor cell proliferation, blood supply and the like, the method disclosed by the invention intervenes aiming at a tumor nutrition metabolic pathway, and can weaken the metabolic adaptation and proliferation capacity of metastatic tumor cells in the liver more specifically. Experimental results show that the functions of targeted inhibition of MUC12 or downstream fructose metabolism key enzymes KHK and ALDOB thereof can significantly reduce the invasion and metastasis ability of tumor cells, and at the same time, normal growth of primary tumors cannot be significantly affected.

The invention discloses a molecular marker for colorectal cancer, and relates to the technical field of colorectal cancer diagnosis, and the molecular marker is TAB2. According to the invention, it is found for the first time that the mRNA level expression of TAB2 in a colonic epithelial cell HcoEpic cell derived from a normal person is significantly higher than the expression of TAB2 in two human colon cancer cells HCT116 and LoVo. The colorectal cancer molecular marker and the molecular marker TAB2 can be applied to preparation of products for diagnosing colorectal cancer and have wide application prospects.

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention discloses a rectal cancer prognosis intelligent analysis method based on two-stage 3D feature extraction. The method comprises the steps of obtaining a prognostic MRI image of a target patient, constructing a 3D convolutional neural network based on a 3D-Unet architecture, performing staged training on the 3D convolutional neural network, and generating a rectal cancer tumor extraction model; taking the preprocessed MRI 3D image as a model input, segmenting a rectal cancer tumor image, and outputting a 3D tumor image and a risk score in stages; and performing prognosis evaluation by combining the risk score with clinical data of the target patient to obtain the survival rate of the target patient. According to the invention, the 3D tumor information in the MRI image can be extracted, the accuracy of prognosis analysis is further enhanced, a more accurate and more reliable prognosis result is provided, and the clinical decision is improved.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

The invention relates to the technical field of image motion analysis, in particular to a rectal cancer radiotherapy effect dynamic monitoring system combined with iconography analysis. Determining a reference recovery index representing the recovery effect from the dimensions of edge change and area change according to the characteristic that the lesion area becomes smaller and smaller along with the better and better treatment effect; then, based on the reference recovery index and in combination with the characteristic that rectum tissue circularity can cause gradual inward contraction of a lesion area and the edge is smoother and smoother, determining a more accurate shape recovery degree representing the reference recovery index; therefore, the corrected radiotherapy recovery curve is corrected more accurately according to the shape recovery degree, and dynamic monitoring of the rectal cancer radiotherapy effect is more visual and accurate.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic compound and a preparation method and application thereof.The phenolic compound is a pair of diastereoisomers, the formula I of the phenolic compound is dextroisomer and is named as (+)-fresh bamboo juice phenol B, and the formula II of the phenolic compound is levoisomer and is named as (-)-fresh bamboo juice phenol B. A pair of diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B are successfully obtained from fresh bamboo juice, and the diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B have remarkable inhibition effects on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body through in-vitro cell tests; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention provides a rectal cancer patient management method and system based on postoperative rehabilitation data analysis, and relates to the field of postoperative rehabilitation management. And executing cross-scene associated feature anomaly recognition to extract a sensitive feature variable set as observation input of the hidden Markov model, driving a rehabilitation stage transition probability to calculate and output a state anomaly feature combination, comparing and positioning a real-time rehabilitation state, calculating and outputting a dynamic rehabilitation stage switching time window, and sending the dynamic rehabilitation stage switching time window to a medical end screen display. The technical problems in the prior art that rehabilitation stage division is extensive, rehabilitation stage switching prediction precision of individual users is insufficient, and rehabilitation management suitability is affected are solved. The technical effects of eliminating the rehabilitation stage division lag effect, performing rehabilitation stage switching accurate prediction and providing high-reliability time sequence feature support for rehabilitation management are achieved.